Results from the Anti-CD3 mAb (teplizumab) prevention trial
Tuesday, 17 September 2019, 13:15 - 14:15, Vilanova Hall
Chair: L. Chatenoud, FR
K.C. Herold, US: Clinical data, background, results, features of the participants associated with clinical responses; conclusions and significance
P.S. Linsley, US: Studies of the mechanism of teplizumab
A.G. Ziegler, DE: Commentary